361 Capital LLC grew its holdings in OraSure Technologies, Inc. (NASDAQ:OSUR) by 296.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 107,066 shares of the medical instruments supplier’s stock after purchasing an additional 80,092 shares during the period. 361 Capital LLC owned about 0.18% of OraSure Technologies worth $2,409,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds have also added to or reduced their stakes in the company. First Mercantile Trust Co. purchased a new stake in OraSure Technologies in the second quarter worth $104,000. Pinebridge Investments L.P. purchased a new stake in OraSure Technologies in the second quarter worth $131,000. Victory Capital Management Inc. increased its stake in OraSure Technologies by 17.6% in the second quarter. Victory Capital Management Inc. now owns 9,070 shares of the medical instruments supplier’s stock worth $157,000 after purchasing an additional 1,360 shares during the period. ARP Americas LLC purchased a new stake in OraSure Technologies in the third quarter worth $221,000. Finally, Noesis Capital Mangement Corp purchased a new position in shares of OraSure Technologies during the third quarter valued at $225,000. Institutional investors and hedge funds own 92.93% of the company’s stock.
In other OraSure Technologies news, insider Brian Smith sold 3,075 shares of the firm’s stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $21.09, for a total value of $64,851.75. Following the completion of the sale, the insider now owns 24,540 shares of the company’s stock, valued at $517,548.60. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Douglas A. Michels sold 22,923 shares of the firm’s stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $23.00, for a total value of $527,229.00. The disclosure for this sale can be found here. Insiders sold 61,110 shares of company stock worth $1,362,463 in the last quarter. 6.40% of the stock is owned by insiders.
ILLEGAL ACTIVITY WARNING: “OraSure Technologies, Inc. (OSUR) Holdings Increased by 361 Capital LLC” was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://stocknewstimes.com/2017/11/17/orasure-technologies-inc-osur-holdings-increased-by-361-capital-llc.html.
OraSure Technologies, Inc. (OSUR) traded up $0.25 on Friday, reaching $14.09. The company’s stock had a trading volume of 657,000 shares, compared to its average volume of 870,090. OraSure Technologies, Inc. has a 52 week low of $8.21 and a 52 week high of $23.01. The stock has a market capitalization of $854.53, a price-to-earnings ratio of 26.61, a PEG ratio of 2.66 and a beta of 1.39.
OraSure Technologies (NASDAQ:OSUR) last posted its earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.09 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.09. OraSure Technologies had a return on equity of 14.12% and a net margin of 20.48%. The company had revenue of $42.30 million for the quarter, compared to analyst estimates of $40.87 million. During the same quarter in the previous year, the firm earned $0.11 earnings per share. The firm’s quarterly revenue was up 31.0% compared to the same quarter last year. equities analysts anticipate that OraSure Technologies, Inc. will post 0.42 EPS for the current year.
Several equities analysts have recently commented on OSUR shares. BidaskClub lowered OraSure Technologies from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 24th. Canaccord Genuity raised their price target on OraSure Technologies from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday, August 3rd. Zacks Investment Research lowered OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Friday, September 8th. Finally, Jefferies Group LLC restated a “buy” rating and set a $20.00 price target on shares of OraSure Technologies in a research note on Tuesday, September 12th. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. OraSure Technologies has an average rating of “Buy” and an average target price of $18.21.
OraSure Technologies Company Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSUR).
Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.